Upregulation of keratin 15 is required for varicella-zoster virus replication in keratinocytes and is attenuated in the live attenuated vOka vaccine strain.


Journal

Virology journal
ISSN: 1743-422X
Titre abrégé: Virol J
Pays: England
ID NLM: 101231645

Informations de publication

Date de publication:
09 Oct 2024
Historique:
received: 14 11 2023
accepted: 22 09 2024
medline: 10 10 2024
pubmed: 10 10 2024
entrez: 9 10 2024
Statut: epublish

Résumé

Varicella-zoster virus (VZV) is the etiological agent of chickenpox and shingles, diseases characterised by epidermal virus replication in skin and mucosa and the formation of blisters. We have previously shown that VZV infection has a profound effect on keratinocyte differentiation, altering the normal pattern of epidermal gene expression. In particular, VZV infection reduces expression of suprabasal keratins 1 and 10 and desmosomal proteins, disrupting epidermal structure to promote expression of a blistering phenotype. Here, we extend these findings to show that VZV infection upregulates the expression of keratin 15 (KRT15), a marker expressed by basal epidermal keratinocytes and hair follicles stem cells. We demonstrate that KRT15 is essential for VZV replication in the skin, since downregulation of KRT15 inhibits VZV replication in keratinocytes, while KRT15 exogenous overexpression supports viral replication. Importantly, our data show that VZV upregulation of KRT15 depends on the expression of the VZV immediate early gene ORF62. ORF62 is the only regulatory gene that is mutated in the live attenuated VZV vaccine and contains four of the five fixed mutations present in the VZV Oka vaccine. Our data indicate that the mutated vaccine ORF62 is not capable of upregulating KRT15, suggesting that this may contribute to the vaccine attenuation in skin. Taken together our data present a novel association between VZV and KRT15, which may open a new therapeutic window for a topical targeting of VZV replication in the skin via modulation of KRT15.

Identifiants

pubmed: 39385182
doi: 10.1186/s12985-024-02514-8
pii: 10.1186/s12985-024-02514-8
doi:

Substances chimiques

Vaccines, Attenuated 0
Immediate-Early Proteins 0
Viral Envelope Proteins 0
Chickenpox Vaccine 0
IE62 protein, Human herpesvirus 3 0
Trans-Activators 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

253

Subventions

Organisme : NIH HHS
ID : R01AI158510
Pays : United States
Organisme : NIH HHS
ID : R01AI158510
Pays : United States
Organisme : NIH HHS
ID : R01AI158510
Pays : United States
Organisme : MRC Grand Challenge in Experimental Medicine
ID : MR/M003833/1
Organisme : MRC Grand Challenge in Experimental Medicine
ID : MR/M003833/1
Organisme : MRC Grand Challenge in Experimental Medicine
ID : MR/M003833/1

Informations de copyright

© 2024. The Author(s).

Références

Arvin AM. Varicella-Zoster virus. Clin Microbiol Rev. 1996;9:361–81.
doi: 10.1128/CMR.9.3.361 pubmed: 8809466 pmcid: 172899
Gershon AA, Breuer J, Cohen JI, Cohrs RJ, Gershon MD, Gilden D, et al. Varicella Zoster virus infection. Nat Rev Dis Primers. 2015;1:1–18.
doi: 10.1038/nrdp.2015.16
Moffat JF, Stein MD, Kaneshima H, Arvin AM. Tropism of varicella-zoster virus for human CD4 + and CD8 + T lymphocytes and epidermal cells in SCID-hu mice. J Virol. 1995;69:5236–42.
doi: 10.1128/jvi.69.9.5236-5242.1995 pubmed: 7636965 pmcid: 189355
Moffat JF, Zerboni L, Kinchington PR, Grose C, Kaneshima H, Arvin AM. Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse. J Virol. 1998;72:965–74.
doi: 10.1128/JVI.72.2.965-974.1998 pubmed: 9444989 pmcid: 124567
Candi E, Schmidt R, Melino G. The cornified envelope: a model of cell death in the skin. Nat Rev Mol Cell Biol. 2005;6:328–40.
doi: 10.1038/nrm1619 pubmed: 15803139
Fuchs E, Cleveland DW. A structural scaffolding of Intermediate filaments in Health and Disease. Science. 1998;279:514–9.
doi: 10.1126/science.279.5350.514 pubmed: 9438837
Moll R, Divo M, Langbein L. The human keratins: biology and pathology. Histochem Cell Biol. 2008;129:705–33.
doi: 10.1007/s00418-008-0435-6 pubmed: 18461349 pmcid: 2386534
Muraki R, Iwasaki T, Sata T, Sato Y, Kurata T. Hair follicle involvement in herpes zoster: pathway of viral spread from ganglia to skin. Virchows Arch. 1996;428:275–80.
pubmed: 8764937
Jones M, Dry IR, Frampton D, Singh M, Kanda RK, Yee MB, et al. RNA-seq analysis of Host and viral gene expression highlights Interaction between Varicella Zoster Virus and Keratinocyte differentiation. PLoS Pathog. 2014;10:e1003896.
doi: 10.1371/journal.ppat.1003896 pubmed: 24497829 pmcid: 3907375
Tommasi C, Rogerson C, Depledge DP, Jones M, Naeem AS, Venturini C, et al. Kallikrein-mediated cytokeratin 10 degradation is required for Varicella Zoster Virus Propagation in skin. J Invest Dermatol. 2020;140:774–e78411.
doi: 10.1016/j.jid.2019.08.448 pubmed: 31626786
Tommasi C, Breuer J. The Biology of Varicella-Zoster Virus Replication in the skin. Viruses. 2022;14:982.
doi: 10.3390/v14050982 pubmed: 35632723 pmcid: 9147561
Reichelt M, Brady J, Arvin AM. The replication cycle of varicella-zoster virus: analysis of the kinetics of viral protein expression, genome synthesis, and virion assembly at the single-cell level. J Virol. 2009;83:3904–18.
doi: 10.1128/JVI.02137-08 pubmed: 19193797 pmcid: 2663235
Bisht P, Das B, Kinchington PR, Goldstein RS. Varicella-Zoster Virus (VZV) small noncoding RNAs antisense to the VZV latency-encoded transcript VLT enhance viral replication. J Virol. 2020;94:e00123–20.
doi: 10.1128/JVI.00123-20 pubmed: 32295909 pmcid: 7307171
Weibel RE, Neff BJ, Kuter BJ, Guess HA, Rothenberger CA, Fitzgerald AJ, et al. Live attenuated varicella virus vaccine. Efficacy trial in healthy children. N Engl J Med. 1984;310:1409–15.
doi: 10.1056/NEJM198405313102201 pubmed: 6325909
Zerboni L, Ku CC, Jones CD, Zehnder JL, Arvin AM. Varicella-Zoster virus infection of human dorsal root ganglia in vivo. Proc Natl Acad Sci U S A. 2005;102:6490–5.
doi: 10.1073/pnas.0501045102 pubmed: 15851670 pmcid: 1088374
Depledge DP, Yamanishi K, Gomi Y, Gershon AA, Breuer J. Deep sequencing of distinct preparations of the live attenuated varicella-zoster Virus Vaccine reveals a conserved core of attenuating single-nucleotide polymorphisms. J Virol. 2016;90:8698–704.
doi: 10.1128/JVI.00998-16 pubmed: 27440875 pmcid: 5021409
Depledge DP, Kundu S, Jensen NJ, Gray ER, Jones M, Steinberg S, et al. Deep sequencing of viral genomes provides insight into the evolution and Pathogenesis of Varicella Zoster Virus and its vaccine in humans. Mol Biol Evol. 2014;31:397–409.
doi: 10.1093/molbev/mst210 pubmed: 24162921
Gomi Y, Sunamachi H, Mori Y, Nagaike K, Takahashi M, Yamanishi K. Comparison of the complete DNA sequences of the Oka varicella vaccine and its parental virus. J Virol. 2002;76:11447–59.
doi: 10.1128/JVI.76.22.11447-11459.2002 pubmed: 12388706 pmcid: 136748
Wu Q, Rivailler P, Xu S, Xu W. Comparison of the whole-genome sequence of an Oka Varicella Vaccine from China with other Oka vaccine strains reveals sites putatively critical for Vaccine Efficacy. J Virol. 2019;93:e02281–18.
doi: 10.1128/JVI.02281-18 pubmed: 30728261 pmcid: 6475776
Quinlivan ML, Gershon AA, Al Bassam MM, Steinberg SP, LaRussa P, Nichols RA, et al. Natural selection for rash-forming genotypes of the varicella-zoster vaccine virus detected within immunized human hosts. Proc Natl Acad Sci U S A. 2007;104:208–12.
doi: 10.1073/pnas.0605688104 pubmed: 17182747
Quinlivan M, Breuer J. Clinical and molecular aspects of the live attenuated Oka varicella vaccine. Rev Med Virol. 2014;24:254–73.
doi: 10.1002/rmv.1789 pubmed: 24687808
Breuer J. Molecular Genetic insights into Varicella Zoster Virus (VZV), the vOka Vaccine strain, and the pathogenesis of latency and reactivation. J Infect Dis. 2018;218:S75–80.
doi: 10.1093/infdis/jiy279 pubmed: 30247591
Bose A, Teh MT, Mackenzie IC, Waseem A. Keratin k15 as a biomarker of epidermal stem cells. Int J Mol Sci. 2013;14:19385–98.
doi: 10.3390/ijms141019385 pubmed: 24071939 pmcid: 3821562
Yang R, Wang J, Chen X, Shi Y, Xie J. Epidermal stem cells in Wound Healing and Regeneration. Stem Cells Int. 2020;2020:e9148310.
doi: 10.1155/2020/9148310
Waseem A, Dogan B, Tidman N, Alam Y, Purkis P, Jackson S, et al. Keratin 15 expression in stratified epithelia: downregulation in activated keratinocytes. J Invest Dermatol. 1999;112:362–9.
doi: 10.1046/j.1523-1747.1999.00535.x pubmed: 10084315
Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271–84.
doi: 10.1056/NEJMoa051016 pubmed: 15930418
Peters GA, Tyler SD, Carpenter JE, Jackson W, Mori Y, Arvin AM, et al. The attenuated genotype of varicella-zoster virus includes an ORF0 transitional stop codon mutation. J Virol. 2012;86:10695–703.
doi: 10.1128/JVI.01067-12 pubmed: 22837206 pmcid: 3457260
Zerboni L, Hinchliffe S, Sommer MH, Ito H, Besser J, Stamatis S, et al. Analysis of varicella zoster virus attenuation by evaluation of chimeric parent Oka/vaccine Oka recombinant viruses in skin xenografts in the SCIDhu mouse model. Virology. 2005;332:337–46.
doi: 10.1016/j.virol.2004.10.047 pubmed: 15661165
Sadaoka T, Depledge DP, Rajbhandari L, Breuer J, Venkatesan A, Cohen JI. A variant allele in Varicella-Zoster Virus Glycoprotein B selected during production of the Varicella Vaccine contributes to its attenuation. mBio. 2022;13:e0186422.
doi: 10.1128/mbio.01864-22 pubmed: 35916400
Dickson MA, Hahn WC, Ino Y, Ronfard V, Wu JY, Weinberg RA, et al. Human keratinocytes that Express hTERT and also bypass a p16INK4a-Enforced mechanism that limits life span become Immortal yet retain normal growth and differentiation characteristics. Mol Cell Biol. 2000;20:1436–47.
doi: 10.1128/MCB.20.4.1436-1447.2000 pubmed: 10648628 pmcid: 85304
Ojeh NO, Frame JD, Navsaria HA. In vitro characterization of an artificial dermal scaffold. Tissue Eng. 2001;7:457–72.
doi: 10.1089/10763270152436508 pubmed: 11506734
Grigoryan S, Kinchington PR, Yang IH, Selariu A, Zhu H, Yee M, et al. Retrograde axonal transport of VZV: kinetic studies in hESC-derived neurons. J Neurovirol. 2012;18:462–70.
doi: 10.1007/s13365-012-0124-z pubmed: 22918852 pmcid: 3556991
Eisfeld AJ, Turse SE, Jackson SA, Lerner EC, Kinchington PR. Phosphorylation of the varicella-zoster virus (VZV) major transcriptional regulatory protein IE62 by the VZV open reading frame 66 protein kinase. J Virol. 2006;80:1710–23.
doi: 10.1128/JVI.80.4.1710-1723.2006 pubmed: 16439528 pmcid: 1367140
Kinchington PR, Bookey D, Turse SE. The transcriptional regulatory proteins encoded by varicella-zoster virus open reading frames (ORFs) 4 and 63, but not ORF 61, are associated with purified virus particles. J Virol. 1995;69:4274–82.
doi: 10.1128/jvi.69.7.4274-4282.1995 pubmed: 7769688 pmcid: 189166
Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676–82.
doi: 10.1038/nmeth.2019 pubmed: 22743772

Auteurs

Cristina Tommasi (C)

Infection, Immunity and Inflammation Department, University College London GOS Institute of Child Health, London, UK.

Ohad Yogev (O)

Infection and Immunity Department, University College London, London, UK.
Eleven Therapeutics, Cambridge, UK.

Michael B Yee (MB)

Department of Ophthalmology and of Molecular Microbiology and Genetics, University of Pittsburgh School of Medicine, Pittsburgh, US.
Krystalbio Inc, Pittsburgh, US.

Andriani Drousioti (A)

Infection, Immunity and Inflammation Department, University College London GOS Institute of Child Health, London, UK.

Meleri Jones (M)

Infection and Immunity Department, University College London, London, UK.
UKHSA, Porton Down, UK.

Alice Ring (A)

Infection and Immunity Department, University College London, London, UK.

Manuraj Singh (M)

Dermatology, St. George's Hospital, London, UK.

Inga Dry (I)

Infection and Immunity Department, University College London, London, UK.
The Roslin Institute, Edinburgh, UK.

Oscar Atkins (O)

Infection and Immunity Department, University College London, London, UK.
Francis Crick Institute, London, UK.

Aishath S Naeem (AS)

Infection and Immunity Department, University College London, London, UK.
Dana-Farber Cancer Institute, Boston, US.

Nisha Kriplani (N)

Infection Medicine, University of Edinburgh, Edinburgh, UK.

Arne N Akbar (AN)

Experimental & Translational Medicine, Division of Medicine, University College London, London, UK.

Jürgen G Haas (JG)

Infection Medicine, University of Edinburgh, Edinburgh, UK.

Edel A O'Toole (EA)

Centre for Cell Biology and Cutaneous Research, Blizard Institute, Queen Mary University of London, London, UK.

Paul R Kinchington (PR)

Department of Ophthalmology and of Molecular Microbiology and Genetics, University of Pittsburgh School of Medicine, Pittsburgh, US.

Judith Breuer (J)

Infection, Immunity and Inflammation Department, University College London GOS Institute of Child Health, London, UK. j.breuer@ucl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH